What potential do heterobivalent inhibitors have for the treatment of severe allergic reactions?
Department of Chemical & Biomolecular Engineering, University of Notre Dame, Notre Dame IN 46556, USA.
Michael W
MW
Handlogten
Ana P
AP
Serezani
Mark H
MH
Kaplan
Basar
B
Bilgicer
D000485:Allergens / Q000008:administration & dosage / Q000276:immunology; D000818:Animals; D018926:Anti-Allergic Agents / Q000138:chemical synthesis / Q000276:immunology / Q000627:therapeutic use*; D000915:Antibody Affinity; D000918:Antibody Specificity; D000937:Antigen-Antibody Reactions / Q000187:drug effects; D001666:Binding Sites, Antibody; D003888:Desensitization, Immunologic; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D006207:Half-Life; D006241:Haptens / Q000276:immunology; D006636:Histamine Release / Q000187:drug effects; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000188:drug therapy / Q000276:immunology / Q000517:prevention & control*; D016056:Immunodominant Epitopes / Q000276:immunology; D007073:Immunoglobulin E / Q000276:immunology*; D007140:Immunoglobulin Fab Fragments / Q000276:immunology; D007211:Indoles / Q000138:chemical synthesis / Q000627:therapeutic use*; D008024:Ligands; D008407:Mast Cells / Q000378:metabolism; D009581:Nitrofurans / Q000138:chemical synthesis / Q000627:therapeutic use*
D000485:Allergens; D018926:Anti-Allergic Agents; D006241:Haptens; D016056:Immunodominant Epitopes; D007140:Immunoglobulin Fab Fragments; D007211:Indoles; D008024:Ligands; D009581:Nitrofurans; D007073:Immunoglobulin E